Pharmacological properties of combination therapies for hypertension

American Journal of Hypertension

Volumn 10, Issue 3, 1997, Pages 13S-16S

  Abernethy, Darrell R ^a  

^a Division of Clinical Pharmacology   (United States)

Author keywords

angiotensin converting enzyme inhibitor; angiotensin receptor blocker; antihypertensive therapy; calcium antagonist; combination therapy; diuretic; drug; adrenoceptor blocker

Indexed keywords

AMILORIDE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; NIFEDIPINE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; VERAPAMIL;

DRUG EFFECT; DRUG POTENTIATION; HEMODYNAMICS; HUMAN; HYPERTENSION; PRIORITY JOURNAL; SHORT SURVEY; VASODILATATION;

EID: 0030929736     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00018-6     Document Type: Article

References (20)

1. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med. 327:1992;998-1008.
2. Setaro JF, Black HR. Refractory hypertension. N Engl J Med. 327:1992;543-547.
3. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J. 304:1992;405-412.
4. Bennett WM, McDonald WJ, Kuehnel E, et al. Do diuretics have antihypertensive properties independent of natriuresis? Clin Pharmacol Ther. 22:1977;499-504.
5. O'Neil RG, Boulpaep EL. Effect of amiloride on the apical cell membrane cation channels of a sodium-absorbing, potassium-secreting renal epithelium. J Membr Biol. 50:1979;365-387.
6. 3H] spironolactone (SC-26304). Proc Natl Acad Sci (USA). 71:1974;1431-1435.
7. England H, Turakka H, Tuomilehto J. Combination therapy in hypertension: a population-based study in eastern Finland. 21:1981;1-8.
8. Lewin AJ, Lueg MC, Targum S, Cardenas P. A clinical trial evaluating the 24-hour effects of bisoprolol/hydrochlorothiazide 5 mg/6.25 mg combination in-patients with mild to moderate hypertension. Clin Cardiol. 16:1993;732-736.
9. Insel PA, Motulsky HJ. A hypothesis linking intracellular sodium, membrane receptors, and hypertension. Life Sci. 34:1984;1009-1013.
10. van der Meiracker AH, Man in't Veld AJ, Ritsema van Eck HJ, et al. Hemodynamic and hormonal adaptations to beta-adrenoceptor blockade. A 24-hour study of acebutolol, atenolol, pindolol and propanolol in hypertensive patients. Circulation. 78:1988;957-968.
11. Burris JF, Weir MR, Oparil S, et al. An assessment of diltiazem and hydrochlorothiazide in hypertension. JAMA. 263:1990;1507-1512.
12. Abernethy DR, Andrawis NS. Pharmacodynamics of calcium antagonist drugs. Cutler NR, Sramek JJ, Narang PK. Pharmacodynamics and Drug Development: Perspectives in Clinical Pharmacology. 1994;253-266 John Wiley and Sons, Ltd, New York.
13. Psaty BM, Heckbert SR, TKoepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA. 274:1995;620-625.
14. Captopril: evaluation of low doses, twice-daily doses, and the addition of diuretic for the treatment of mild to moderate hypertension. Clin Sci. 63:((suppl 8)):1982;4435-4455.
15. Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. N Engl J Med. 319:1988;1517-1525.
16. Weber MA, Byyny RL, Pratt JH, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 155:1995;405-411.
17. Wong PC, Price WA, Chin AT, et al. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 252:1990;719-725.
18. Dahlöf B, Eggertsen R, Hansson L. Calcium antagonists combined with beta-blockers or ACE inhibitors in the treatment of hypertension. J Cardiovasc Pharmacol. 12:((suppl 6)):1988;S104-S108.
19. Guazzi MD, DeCesare N, Galli C, et al. Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension. Circulation. 70:1984;279-284.
20. Dollery CT. Pharmacological basis for combination therapy of hypertension. Ann Rev Pharmacol Toxicol. 17:1977;311-323.